KyungDong Pharm home
Prescription Medicines

Pyrocin Tab.

Product Category
Broad-spectrum macrolide antibiotics
Active Ingredients
Clarithromycin
Appearance
Yellow, oval, film-coated tablets with vanilla flavor
Reimbursement Code
648102230
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Clarithromycin (KP) ----- 250mg (potency)
- Additives (preservatives): Sorbic acid (NF) -------- 0.55mg
- Additives (tar coloring): Yellow No. 203
- Other additives: microcrystalline cellulose, vanillin, sorbitan oleate, stearic acid, magnesium stearate, pregelatinized starch, colloidal silicon dioxide, croscarmellose sodium, talc, povidone, propylene glycol, hydroxypropyl cellulose, hypromellose 2910


2. Effectiveness
○ Effective bacterial species
Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes (group A beta-hemolytic), Listeria monocytogenes, Streptococcus agalactiae (group B), viridans streptococci, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Legionella pneumophila, Bordetella pertussis, Campylobacter jejuni, Helicobacter pylori, Neisseria gonorrhoeae, organisms causing animal pasteurellosis, Mycoplasma pneumoniae, Chlamydia trachomatis, Clostridium perfringens, Peptococcus niger, Propionibacterium acnes, Bacteroides melaninogenicus, Mycobacterium avium and Mycobacterium intracellulare
○ Indications
- Lower respiratory tract infections: bronchitis, pneumonia, etc.
- Upper respiratory tract infections: pharyngitis, sinusitis, etc.
- Skin and skin tissue infections
- Mycobacterial infections caused by Mycobacterium avium and Mycobacterium intracellulare
- Eradication of Helicobacter pylori in duodenal ulcer patients

3. Dosage and dosage
○ Adults: Clarithromycin is usually administered at a dose of 250 mg (potency) twice a day, and in case of severe infections, a dose of 500 mg (potency) at a time is administered twice a day. The administration period is usually 7 to 14 days. For patients with renal failure whose creatinine clearance rate is less than 30 mL/min, the dose should be reduced by half.
That is, 250mg (titer) is administered once a day, and in case of severe infection, 250mg (titer) is administered twice a day. Do not administer for more than 14 days to these patients.
○ Mycobacterial infection: Administer 500 mg (potency) at a time, twice a day. In this case, it must be administered in combination with other antimycobacterial agents such as ethambutol, clofazimine, and rifampin.
○ Eradication of Helicobacter pylori in patients with duodenal ulcer: Administer 500 mg (potency) 3 times a day as this drug in combination with omeprazole 40 mg once a day for 14 days, and administer omeprazole 40 mg once a day for 14 consecutive days. That is, clarithromycin is administered at a dose of 500 mg (titer) three times a day for 14 days (days 1 to 14), and omeprazole is administered at a dose of 40 mg once a day for 28 days (days 1 to 28).
○ Children over 12 years of age use the same medication as adults, children under 12 years of age use clarithromycin dry syrup.

4. Precautions for use
1. Do not administer to the following patients:
1) Patients with hypersensitivity to the excipients of this drug
2) Patients with a history of hypersensitivity to clarithromycin, erythromycin, or macrolide antibiotics
3) Patients receiving terfenadine, cisapride, pimozit, astemizole, and domperidone [when administered in combination with clarithromycin and/or erythromycin, QT prolongation and cardiac arrhythmias (including ventricular tachycardia, ventricular fibrillation, and torsades de pointes) occur because hepatic metabolism of these drugs is disturbed by clarithromycin and erythromycin. This was reported as a result of post-marketing surveillance in foreign countries. Fatal cases have also been reported.] (Refer to ‘5. Interaction’)
4) Patients with a history of QT prolongation or ventricular cardiac arrhythmia (including torsades de pointes)
5) Patients with severe liver impairment
6) Patients with renal impairment whose creatinine clearance rate is less than 30mL/min (limited to extended-release tablets)
7) Patients receiving ergot alkaloids and their derivatives (ergotamine, dihydroergotamine, etc.) [Ergot toxicity may occur.]
8) Pregnant and lactating women
9) Patients with central nervous system infection
10) Patients receiving mizolastine or bepridil
11) Patients receiving lovastatin or simvastatin (refer to ‘5. Interaction’)
12) Patients receiving ticagrelor
13) Patients receiving colchicine
14) Patients with hypokalemia
15) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. (Limited to products containing lactose)

2. Administer with caution to the following patients:
1) Patients with hepatic impairment (mainly excreted through the liver)
2) Patients with moderate to severe renal failure (blood concentration may increase.)
3) Patients with heart disease [Can cause QT prolongation and ventricular arrhythmia (including torsades de pointes)]
4) Elderly people
5) Patients receiving other antibiotics (macrolides, lincomycin, clindamycin, chloramphenicol, etc.) (Be careful of cross-resistance.)
6) Patients receiving bromocriptine, cabegoline, pergolide, ebastin, tacrolimus, tolterodine, and halofantrine
7) When administering to patients allergic to drugs (especially when administering drugs with a similar structure to the ingredients of this drug), administer with caution.

3. Adverse reactions
1) Shock and anaphylactoid symptoms: In rare cases, shock and anaphylactoid symptoms (difficulty breathing, convulsions, redness, etc.) may occur, so observe thoroughly and if adverse reactions occur, stop administration and take appropriate measures.
2) Hypersensitivity reaction: Sometimes rash, rarely itching, hives, mild skin redness, angioedema, joint swelling, drug rash, etc. may occur.
3) Digestive system: There are occasional reports of gastrointestinal disorders such as abdominal distension, nausea, vomiting, indigestion, abdominal pain/discomfort, gassiness, diarrhea, oral erosion, epigastric pain (rarely in the form of cramps), dry mouth, transient tooth discoloration, rarely pancreatitis, increased amylase, abnormal taste, loss of appetite, constipation, and tongue discoloration. Colitis accompanied by bloody stool, such as pseudomembranous colitis or hemorrhagic colitis, may occur. If abdominal pain or frequent diarrhea occurs, discontinue administration and take appropriate measures.
Rare cases of this medicine being found in the stool have been reported in patients with shortened gastrointestinal transit time due to anatomical or functional gastrointestinal conditions, such as ileostomy or colostomy (extended-release tablets only).
4) Respiratory system: Fever, cough, difficulty breathing, abnormal chest Acute exacerbations of chronic bronchitis and acute maxillary sinusitis were also observed.
5) Blood system: Occasionally, an increase in eosinophils, a decrease in platelets, a decrease in pancytosis, hemolytic anemia, a decrease in leukocytes, and agranulocytosis may occur, so conduct regular tests and observe sufficiently. If any adverse reactions occur, take appropriate measures, such as discontinuing administration.
6) Central nervous system: There have been reports of transient central nervous system adverse reactions such as dizziness, depression, loss of taste, loss of smell, anxiety, rarely insomnia, nightmares, tinnitus, confusion, disorientation, hallucinations, psychosis, depersonalization, convulsions (tonic clonus, myoclonus, loss of consciousness seizures, etc.), tremors, and paralysis, but it has not been determined whether they are related to this drug. Behavioral changes and manic behavior appear, but disappear when drug administration is stopped. Since various adverse reactions may occur, observe thoroughly, and if adverse reactions occur, discontinue administration and take appropriate measures.
7) Skin: Stevenson-Johnson syndrome, toxic epidermal necrolysis, etc. may be found, so observe carefully. If any adverse reactions occur, discontinue administration and take appropriate measures, such as administration of corticosteroids. Since allergic purpura may occur, observe thoroughly, and if any adverse reactions occur, discontinue administration and take appropriate measures. During post-marketing experience, ‘DRESS (drug rash with eosinophilla and systemic symptoms)’ occurred.
8) Liver: As with other macrolide antibiotics, there are rare reports of hepatocellular or cholestatic hepatitis with or without jaundice and liver dysfunction, including increased liver enzyme levels. This liver dysfunction can be severe and is usually reversible. In some cases, liver failure with fatal outcome has been reported, which is usually associated with severe underlying disease and/or concomitantly administered medications. Liver dysfunction, jaundice, and liver failure accompanied by fulminant hepatitis, increased AST, ALT, γ-GTP, LDH, ALP, and increased total bilirubin may occur, so observe thoroughly. If symptoms and signs of hepatitis such as loss of appetite, jaundice, dark urine, itching, or abdominal tenderness appear, stop administration and take appropriate measures.
9) Kidney: There have been reports of rare increases in serum creatinine, but it has not been revealed whether it is related to this drug. There are rare reports that BUN increases at high doses. Interstitial nephritis, renal failure, and pancreatitis have been reported. Since rhabdomyolysis, which is characterized by muscle pain, weakness, elevated CPK, and elevated myoglobin in the blood and urine, may occur, conduct sufficient observation, and if adverse reactions occur, discontinue administration and take appropriate measures. Be careful as acute renal failure due to rhabdomyolysis may occur. If symptoms such as oliguria or decreased renal function such as an increase in serum creatinine level occur, discontinue administration and take appropriate measures.
10) Mycosis: There are rare reports of glossitis, stomatitis, and oral candidiasis.
11) Circulatory system: Like other macrolides, QT prolongation, ventricular tachycardia, and torsades de pointes have been rarely reported.
12) Others: There are rare reports of malaise, headache, loss of taste, reversible hearing loss, paresthesia, joint pain, muscle pain, and olfactory impairment. Tinnitus and hearing impairment can generally decrease when dosing is stopped, but may reappear when more than 1g per day is administered during an extended dosing period. There have been reports of rare cases of hypoglycemia in patients receiving oral hypoglycemic drugs or insulin. Rhabdomyolysis has been reported in post-marketing experience. In some reports of rhabdomyolysis, clarithromycin has been administered in combination with statins, fibrates, colchicine, or allopurinol.
13) There were post-marketing reports that colchicine toxicity occurred when administered in combination with colchicine, especially in the elderly and some patients with renal failure. Deaths have also been reported in some of these patients.
14) In a limited number of pediatric patients with AIDS treated for mycobacterial infection, the most frequently reported adverse reactions, excluding those attributable to concurrent conditions, were tinnitus, hearing impairment, vomiting, nausea, abdominal pain, purpuric rash, pancreatitis, and increased amylase. Analysis of markedly abnormal laboratory values showed markedly elevated total bilirubin in one pediatric patient receiving <15 mg/kg/day. Among patients receiving doses from 15 to <25 mg/kg/day, markedly abnormal SGPT and BUN values and a marked decrease in platelet count were each reported in one patient. No markedly abnormal laboratory values were reported in patients receiving the highest dose (≤25 mg/kg/day). This information applies to the dry syrup formulation only.
15) When analyzing the seriously abnormal levels (upper and lower limits) of certain tests in patients with weakened immune function, AST and ALT rose to seriously abnormal levels in approximately 2-3% of patients administered approximately 1000 mg per day, and white blood cell and platelet counts were abnormally low. Additionally, BUN was elevated in a smaller number of patients (limited to regular tablets).
16) Adverse reactions that may be related to clarithromycin are shown in the table below according to systemic tissue classification and frequency classification as follows: very common (≥ 1/10), common (≥ 1/100~< 1/10), rare (≥ 1/1000~1/100), and not known (adverse reactions that occurred in post-marketing surveillance and cannot be estimated from data). In each column, if seriousness can be assessed, adverse reactions are listed in descending order of severity.
* Please refer to the attached document for detailed tables.

4. General precautions
1) When using this drug, in order to prevent the development of resistant bacteria, it is advisable to confirm sensitivity and administer only the minimum period necessary for treatment.
2) As with other antibiotics, infection by non-susceptible bacteria or fungi may occur, so in such cases, discontinue administration and take appropriate measures.
3) If an allergic reaction occurs to this drug, discontinue administration.
4) Severe allergic reactions may require epinephrine, antihistamines, or corticosteroids.
5) There are reports that almost all antibiotics, including macrolides, cause pseudomembranous colitis ranging from mild to severe. Clostridium difficile-associated diarrhea (CDAD) has been reported with use of almost all antibiotics, including this drug, and can range from mild diarrhea to fatal colitis. It is important to diagnose patients receiving antibiotics, including this drug, with persistent diarrhea. The use of antibiotics can cause changes in the intestinal flora, causing overgrowth of Clostridium. Studies have shown that toxins produced by Clostridium difficile are the main cause of antibiotic-related colitis. Once a diagnosis of pseudomembranous colitis is made, treatment should be initiated. Mild pseudomembranous colitis can be reversed by discontinuing medication. In moderate or severe cases, treatment includes fluid, electrolyte, and protein supplementation, and treatment with antibiotics that are clinically effective against Clostridium difficile.
Clostridium difficile-associated diarrhea (CDAD) should be considered in all patients who develop diarrhea following the use of antibiotics. Clostridium difficile-related diarrhea (CDAD) has been reported even more than 2 months after antibiotic administration, so careful management of patient history is required.
6) As a result of some studies on HIV-positive patients receiving this drug for the treatment of Mycobacterium avium complex infection (MAC), a low survival rate was observed in patients receiving high doses of 500 mg or more twice a day. There is no interpretation of the results of this study, but when using this drug for the treatment or prevention of MAC, the appropriate dose of 500 mg twice daily should not be exceeded.
7) For patients with renal dysfunction with or without liver dysfunction, it is appropriate to reduce the dose and extend the administration interval.
8) For information on precautions for combined use with other drugs, refer to the instructions for use of each drug.
9) Resistant bacteria may overgrow due to repeated administration and long-term use. If bacterial hyperplasia occurs, discontinue administration of this drug and implement appropriate countermeasures.
10) There are reports that Helicobacter pylori bacteria show resistance in a small number of patients.
11) If you take 1g (potency) or more than 1g (potency) per day for a long period of time, tinnitus or hearing loss may occur, but it can be recovered if you stop taking the drug.
12) Although a causal relationship has not been established, tooth discoloration has occurred in some cases and can generally be recovered with dental treatment.
13) There are reports that resistance has emerged in HIV-positive patients receiving this drug for the prevention and treatment of Mycobacterium avium complex infection (MAC).
14) Patients with AIDS and other immunocompromised patients receive this drug for a long period of time for mycobacterial infections, and it is difficult to distinguish between adverse reactions and this drug due to existing HIV or concurrent diseases (limited to general tablets and dry syrups).
15) Worsening of myasthenia gravis has been reported in patients receiving clarithromycin.
16) Because of the risk of QT prolongation, caution should be exercised when using this drug in patients with medical conditions associated with an increased predisposition to QT prolongation and torsades de pointes.
17) Considering the recently developed resistance of Streptococcus pneumoniae to macrolides, it is important to perform a susceptibility test when prescribing this drug for the treatment of community-acquired pneumonia. In case of hospital-acquired pneumonia, this drug should be used in combination with additional appropriate antibiotics.
18) Mild or moderate skin and soft tissue infections are usually caused by Staphylococcus aureus and Streptococcus pyogenes, which may be resistant to macrolides, so it is important to perform susceptibility testing.
19) If a severe acute hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, Henoch-Schonlein purpura, acute generalized exanthematous pustulosis (AGEP), etc.) occurs, administration of this drug should be discontinued immediately and appropriate treatment should be promptly administered.
20) There is no data on the effect of this drug on the ability to drive or operate machinery. Since vestibular and non-vestibular vertigo, confusion, and disorientation may occur with drug administration, patients should take this into account before driving or operating machinery.
21) Epidemiological studies investigating the risk of cardiovascular disease caused by macrolide antibiotics showed diverse results. Some observational studies have identified a rare short-term risk of arrhythmias, myocardial infarction, and cardiovascular death associated with macrolides, including clarithromycin. These results should be considered in balance with the therapeutic effect when prescribing clarithromycin.

5. Interaction
1) Do not administer in combination with other ototoxic drugs, especially aminoglycosides.
2) When co-administered with theophylline or carbamazepine, it has been reported that the serum concentration of these drugs increases. Therefore, if a high dose of theophylline is administered or the basal concentration of theophylline is in the upper therapeutic range, monitoring of the blood concentration of theophylline should be considered. When co-administered with carbamazepine, monitoring of the blood concentration of theophylline may be considered. In a clinical trial in which theophylline extended-release tablets 6.5 mg/Kg or 12 mg/Kg were co-administered with 250 mg or 500 mg of this drug every 12 hours, the steady-state Cmax, Cmin and area under the curve (AUC) of theophylline increased by approximately 20%.
3) ① Drugs metabolized by the cytochrome P450 system (warfarin, ergot alkaloids, triazolam, midazolam, lovastatin, simvastatin, atorvastatin, disopyramide, phenytoin, cyclosporine, hexobarbital, alfentanil, bromocriptine, valproate, methylprednisolone, sildenafil, vinblastine, When administered in combination with alprazolam, astemizole, carbamazepine, cilostazol, cisapride, omeprazole, pimojit, quinidine, rifabutin, tacrolimus, terfenadine, and domperidone, serum concentrations of these drugs may increase like other macrolide antibiotics.
② Potent inducers of the cytochrome P450 metabolic system, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine, promote the metabolism of clarithromycin, lowering the plasma concentration of clarithromycin, while increasing the plasma concentration of 14-OH-clarithromycin, a microbiologically active metabolite. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, co-administration of the above enzyme inducers and clarithromycin may not produce the intended therapeutic effect.
③ Drugs that are CYP3A inducers (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort) may induce the metabolism of this drug. This may lead to sub-therapeutic levels of this drug, resulting in reduced efficacy. In addition, because the plasma concentration of CYP3A inducers may increase due to the CYP3A inhibitory effect of this drug, it may be necessary to monitor this (refer to the approval information related to the administered CYP3A inducer).
4) Drug interactions related to CYP3A enzymes have also been reported with erythromycin and/or clarithromycin components as follows.
Clarithromycin is known to inhibit CYP3A, and co-administration with drugs mainly metabolized by CYP3A is associated with an increase in drug concentration, which may cause an increase and prolongation of the therapeutic effect and adverse reactions of the co-administered drug. Clarithromycin should be used cautiously in patients receiving drugs known to be substrates of the CYP3A enzyme, especially other drugs that have a narrow safety margin (e.g., carbamazepine) and/or are primarily metabolized by this enzyme. Dose adjustments may be considered when possible, and patients receiving clarithromycin should carefully monitor serum concentrations of drugs primarily metabolized by CYP3A.
① When administered in combination with terfenadine, there are rare reports of cardiovascular adverse reactions such as QT prolongation, ventricular arrhythmia (including torsades de pointes), cardiac arrest (including death), ventricular tachycardia, and ventricular fibrillation, so do not administer concurrently. There are reports that similar results were obtained when astemizole was coadministered with other macrolide antibiotics.
② There are reports that cisapride concentration increased when administered concurrently with cisapride. This can lead to QT prolongation and arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsades de pointes. There are reports that similar effects occurred when administered in combination with pimojit, so do not administer in combination.
③ Co-administration of this drug with lovastatin or simvastatin is contraindicated. Like other macrolide drugs, this drug has been reported to increase the concentration of HMG-CoA reductaseinhibitor. Rare cases of rhabdomyolysis have been reported in patients receiving these drugs concomitantly. Patients should be monitored for signs and symptoms of myopathy. Rhabdomyolysis has also been rarely reported in patients receiving this drug in combination with atorvastatin or rosuvastatin. When coadministered with clarithromycin, the lowest possible dose of atorvastatin or rosuvastatin should be administered. Adjustment of statin dose or use of statins that do not affect CYP3A metabolism (e.g. fluvastatin or pravastatin) should be considered.
④ When midazolam and clarithromycin tablets (500 mg administered twice daily) were coadministered, midazolam AUC increased 2.7 times after intravenous administration and 7 times after oral administration. Midazolam and clarithromycin should not be administered orally together. When midazolam and clarithromycin are coadministered intravenously, patients should be closely monitored for dose adjustment.
The same precautions apply to other benzodiazepines metabolized by CYP3A, including triazolam and alprazolam. For benzodiazepines that are not metabolized by CYP3A (temazepam, nitrazepam, lorazepam), the interaction with clarithromycin is not clinically significant.
In foreign post-marketing studies, central nervous system effects such as drowsiness and confusion were reported when this drug and triazolam were administered together. Patients with increased pharmacological activity of the central nervous system require monitoring.
⑤ There have been post-marketing reports that Torsades de Pointes occurred when administered in combination with quinidine or disopyramide. Monitor blood levels of these drugs and electrocardiograms for QT prolongation.
In post-marketing surveillance, there were reports that hypoglycemia occurred when administered in combination with disopyramide. Therefore, blood sugar must be monitored during administration.
⑥ When administered in combination with ergotamine or dihydroergotamine, acute ergot toxicity characterized by symptoms such as vasospasm and ischemia of tissues including the limbs and central nervous system may occur. Coadministration of clarithromycin with these drugs is contraindicated.
⑦ Sildenafil, tadalafil, vardenafil;
Each of these phosphodiesterase inhibitors is metabolized at least in part by CYP3A, and CYP3A is inhibited by coadministered clarithromycin. Co-administration of the above drugs with clarithromycin will result in increased phosphodiesterase inhibitory activity. When clarithromycin and the above drugs are administered together, a dose reduction of the above drugs should be considered.
5) Digoxin is considered to be a substrate of P-glycoprotein (Pgp), an efflux transporter. Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered together, inhibition of Pgp by clarithromycin causes an increase in digoxin levels.
There are reports that digoxin increases the serum concentration, so monitor the serum concentration of digoxin when coadministered with digoxin. Some patients developed clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias.
6) When this drug and zidovudine are administered orally in combination to HIV-infected adult patients, it interferes with the absorption of zidovudine and reduces the steady-state concentration of zidovudine. This interaction has not been observed in pediatric HIV patients treated with zidovudine or dideoxyinosine concomitantly with this drug. There was no statistically significant effect on the pharmacokinetics of didanosine in adult HIV patients (limited to dry syrup preparations).
7) When this drug and zidovudine are administered orally in combination to HIV-infected adult patients, it interferes with the absorption of zidovudine and reduces the steady-state concentration of zidovudine. This drug has been shown to interfere with the absorption of concomitantly administered oral zidovudine, and this interaction can be largely avoided by spacing the doses of this drug and zidovudine. This interaction has not been observed in pediatric HIV patients treated with zidovudine or dideoxyinosine concomitantly with this drug. There was no statistically significant effect on the pharmacokinetics of didanosine in adult HIV patients (limited to extended-release tablets and regular tablets).
8) There was one report that serum concentration slightly increased when administered in combination with lansoprazole, but there is no data to support the results on dose adjustment. When healthy adults were co-administered with 500 mg of clarithromycin every 8 hours and 40 mg of omeprazole once a day, the steady-state Cmax, AUC0-24, and T1/2 of omeprazole increased by 30%, 89%, and 34%, respectively. The average gastric pH within 24 hours was 5.2 when omeprazole was administered alone and 5.7 when administered in combination with this drug.
9) When administered in combination with rifabutin or rifampin, clarithromycin concentration is reduced. Clarithromycin can increase toxicity by increasing the serum and tissue concentration of rifabutin, and increases the risk of uveitis.
10) There is a pharmacokinetic study report that shows that the metabolism of clarithromycin is significantly disrupted when administered in combination with ritonavir. Because the therapeutic range of clarithromycin is wide, dose reduction is not necessary for patients with normal renal function, but dose adjustment is required for patients with renal failure as follows. That is, for patients with a creatinine clearance rate of 30 to 60 mL/min, the dose should be reduced by 50%, and for patients with a creatinine clearance rate of 30 mL/min or less, the dose should be reduced by 75%. When co-administered with ritonavir, the dose of clarithromycin should not exceed 1 g/day. There are reports that metabolic interactions occur when administered in combination with indinavir. However, no dose adjustment is necessary for patients with normal renal function. (Limited to dry syrup and general tablets)
11) There is a pharmacokinetic study report that shows that the metabolism of clarithromycin is significantly disrupted when administered in combination with ritonavir. Because the therapeutic range of clarithromycin is wide, dose reduction is not necessary for patients with normal renal function, but dose adjustment is required for patients with renal failure as follows. That is, patients with a creatinine clearance of 30 to 60 mL/min should reduce the dose by 50% and use the maximum dose of one clarithromycin sustained-release tablet per day. Patients with a creatinine clearance of 30 mL/min or less should not use clarithromycin sustained-release tablets because dose reduction is not possible and use clarithromycin immediate-release tablets. When co-administered with ritonavir, the dose of clarithromycin should not exceed 1 g/day. There are reports that metabolic interactions occur when administered in combination with indinavir. However, dose adjustment is not necessary for patients with normal renal function (extended-release tablets only).
When ritonavir is used as a pharmacokinetic enhancer for other HIV protease inhibitors (including atazanavir and saquinavir) in patients with renal failure, similar dose adjustments should be considered.
12) When administered in combination with tacrolimus, toxicity may increase by increasing the plasma concentration of tacrolimus.
13) When co-administered with amoxicillin and/or omeprazole, refer to the precautions for use and drug interactions for each drug.
14) It is not recommended to use it in combination with ranitidine bismuth citrate therapy in patients with a creatinine clearance of less than 25 mL/min. Do not use ranitidine bismuth citrate in combination with patients with a history of acute porphyria. When administered in combination with ranitidine bismuth citrate, the concentration of ranitidine in the blood increased by 57%, the minimum concentration of bismuth in the blood increased by 48%, and the concentration of 14-hydroxy-clarithromycin increased by 31%, but this has no clinical significance.
15) Clarithromycin and itraconazole are both substrates and inhibitors of CYP3A, causing a two-way drug interaction. Clarithromycin increases the plasma concentration of itraconazole, and itraconazole increases the plasma concentration of clarithromycin. Patients receiving itraconazole and clarithromycin concomitantly should be carefully monitored for signs of increased or prolonged pharmacological activity.
16) When administered in combination with oral hypoglycemic agents (e.g. sulfonyl urea drugs) and/or insulin, significant hypoglycemia may occur. When used in combination with nateglinide, pioglitazone, repaglinide, or rosiglitazone, the CYP3A enzyme may be inhibited by clarithromycin and may cause hypoglycemia. Monitor your blood sugar carefully.
17) Be careful when co-administering with felodipine, as drug excretion may be delayed and the drug effect may increase.
18) When administered in combination with bepridil, mizolastine, or ebastin, there is a risk of ventricular dysfunction, especially torsades de pointes disorder.
19) When administered in combination with cabergoline and pergolide, the action may increase and plasma concentration may increase in case of overdose.
20) When administered in combination with tolterodine, the serum concentration of tolterodine may increase if overdose is administered to patients with slow metabolism. The main metabolic pathway of tolterodine is the 2D6 isoform of cytochrome P450 (CYP2D6), but in the CYP2D6-deficient group, it was found to be metabolized by CYP3A. Inhibition of CYP3A in this population resulted in significant elevations in tolterodine serum concentrations. When a CYP3A inhibitor such as clarithromycin is co-administered to a population with weak CYP2D6 metabolizers (CYP2D6 poor metabolizer), a reduction in the dose of tolterodine is required.
21) When co-administered with halofantrine, there is a risk of ventricular dysfunction, especially torsades de pointes disorder, so if possible, perform a QT test in advance or monitor the electrocardiogram.
22) Changes in INR (international normalized ratio): An increase in anticoagulant activity has been reported in patients receiving antibiotics, including this drug, simultaneously with anticoagulants. Infectious diseases (and accompanying inflammatory processes), age and general condition of the patient are risk factors. When this drug was administered concomitantly with warfarin, there was a risk of serious bleeding and significant increases in INR and prothrombin time. When coadministering this drug with oral anticoagulants, the INR and prothrombin time should be monitored frequently. If necessary, adjust the dose of oral anticoagulant appropriately. It is more severe for some classes of antibiotics, especially fluoroquinolones, macrolides, cyclins, cotrimoxazole and some cephalosporins.
23) Be careful when using in combination with calcium antagonists (nifedipine, verapamil hydrochloride, etc.). Hypotension, bradyarrhythmia, and lactic acidosis have been observed in patients receiving clarithromycin and verapamil together.
24) When 200 mg of fluconazole once daily and 500 mg clarithromycin twice daily were co-administered to healthy volunteers, the average steady-state Cmin and AUC of this drug increased by 33% and 18%, respectively, but the concentration of 14-OH-clarithromycin was not significantly affected. No dose adjustment of clarithromycin is required.
25) When administered in combination with colchicine, colchicine toxicity has been reported, especially in the elderly and some patients with renal failure, and in some cases, deaths have also been reported. Colchicine is a substrate of CYP3A and the efflux transporter P-glycoprotein (Pgp). Clarithromycin and other macrolide antibiotics may increase exposure to colchicine by inhibiting CYP3A and Pgp, so coadministration should be monitored for clinical signs of colchicine toxicity. Colchicine is contraindicated in patients with renal or hepatic impairment who are taking Pgp or strong CYP3A4 inhibitors, so colchicine and this drug should not be coadministered in these patients.
26) Clarithromycin and atazanavir are both substrates and inhibitors of CYP3A, and there is evidence for bi-directional drug interactions. When clarithromycin (500 mg twice daily) and atazanavir (400 mg once daily) are coadministered, the level of clarithromycin is doubled, 14-OH-clarithromycin is decreased by 70%, and the AUC of atazanavir is increased by 28%. Due to the wide therapeutic window of clarithromycin, no dose reduction of clarithromycin is required in patients with normal renal function. For patients with moderate renal function (creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should be reduced by 50%. For patients with creatinine clearance less than 30 mL/min, the dose of clarithromycin should be reduced by 75% according to the appropriate clarithromycin regimen. If the daily dose of clarithromycin exceeds 1000 mg, it should not be administered in combination with protease inhibitors.
27) Clarithromycin and saquinavir are both substrates and inhibitors of CYP3A, and there is evidence for bi-directional drug interactions. When clarithromycin (500 mg twice a day) and saquinavir (soft capsules 1200 mg three times a day) were co-administered to 12 healthy volunteers, the steady-state AUC and C max values ​​of saquinavir increased by 177% and 187% compared to when administered alone. The AUC and Cmax values ​​of clarithromycin increased by approximately 40% compared to when administered alone. No dosage adjustment of either drug is required at the doses/formulations used in the study. The results of drug interaction studies using the saquinavir soft capsule formulation are not representative of the effectiveness of using the hard capsule formulation. The results of drug interaction studies conducted with saquinavir alone are not representative of the effects of saquinavir/ritonavir administration. When saquinavir is administered in combination with ritonavir, the potential effects of ritonavir on clarithromycin should be considered.
28) Clarithromycin exposure was decreased by etraribine, but the concentration of the active metabolite 14-OH-clarithromycin was increased. 14-OH-clarithromycin has reduced activity against Mycobacterium avium complex (14), so total activity against this pathogen may be altered. Therefore, alternatives to this drug should be considered in the treatment of MAC.

6. Administration to pregnant and lactating women
1) Since safety for pregnant women has not been established, it should not be administered to pregnant women or women who may be pregnant.
2) This drug is secreted into breast milk, so it should not be administered to nursing mothers. If administration is unavoidable, breast-feeding should be discontinued. If an infant is being treated with cisapride and is breast-feeding, do not administer this drug to a nursing mother as there may be a drug interaction.

7. Administration to children
1) This drug tablet has not been studied in children under 12 years of age.
2) There have been no studies on this drug's dry syrup in infants under 6 months of age. For pneumonia, there are no studies on dry syrup of this drug in children under 3 years.
3) There are no study results on this drug in patients with MAC under 20 months of age.
4) The tolerability of this drug in immediately postnatal and growing animals was similar to that in growing animals. Young animals show milder intolerance and mild reductions in red blood cells, platelets, and white blood cells following acute overdose. However, toxicity to the liver, kidneys, thymus and reproductive organs was less sensitive.
5) When administered in combination with valproate and phenobarbital to a 3-year-old patient, the concentration of these drugs increased and excessive sedation was observed. Although a cause-effect relationship has not been established, monitoring of valproate and phenobarbital concentrations should be considered.

8. Administration to elderly people
1) In general, elderly people should be administered with caution because their physiological functions may decline and high blood levels may persist.
2) Dose adjustment must be made for elderly patients with severe renal dysfunction.

9. Effect on clinical test values
1) ALT, AST, γ-GTP, ALP, LDH, and total bilirubin levels may increase.
2) BUN level and serum creatinine level may increase, white blood cell count may decrease, and prothrombin time may become longer.
3) Care must be taken when determining the eradication of Helicobacter pylori. The 13C-urea breath test result may be falsely positive while taking proton pump inhibitors such as lansoprazole or antibiotics such as amoxicillin or clarithromycin, or immediately after the end of administration. Therefore, when performing a 13C-urea breath test to determine eradication, it is advisable to conduct it 4 weeks after the end of treatment with this drug.

10. Treatment in case of overdose
1) Symptoms: There are reports of gastrointestinal symptoms occurring due to overdose of this drug. There is a report that a patient with a history of bipolar disorder showed changes in mental administration, obsessive behavior, hypokalemia, and hypoxemia when taking an 8g overdose.
2) Treatment: If adverse reactions occur due to overdose, they must be treated with gastric lavage or auxiliary methods. As with other macrolide antibiotics, no effect is expected from hemodialysis or peritoneal dialysis.

11. Application precautions
In pharmacokinetic studies on normal subjects, it has been reported that the absorption of this drug is reduced when used in combination with natural aluminum silicate.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Validity period
24 months from date of manufacture

Product Updates

Total 9items

No.Product NameDetailsDate of ChangeDownload
9Pyrocin Tab.Precautions for use2019.10.10PDFPrecautions for use of clarithromycin single agent (tablet) (draft).pdf
8Pyrocin Tab.Precautions for use2018.09.05PDF0063_199902270_Precautions for use_Pyrosinjeong.pdf
7Pyrocin Tab.Pyrosin tablets (precautions for use)2016.08.16HWPClarithromycin single oral tablet_tablet unification adjustment plan.hwp
6Pyrocin Tab.Pyrosin Tablet (Dosage, Precautions for Use)2012.11.09HWPPyro New Year_Change Permission.hwp
5Pyrocin Tab.Pyrosin tablets (precautions for use)2011.05.20HWPPyrosinjeong (Precautions for use).hwp
4Pyrocin Tab.Pyrosin tablets (precautions for use)2007.07.20HWP9-4. Pyrosinjeong (Precautions for use) (2007.07.20).hwp
3Pyrocin Tab.Pyrosin tablets (precautions for use)2009.04.14HWP9-3. Pyrosinjeong (Precautions for use) (2009.04.14).hwp
2Pyrocin Tab.Pyrosin tablets (efficacy, dosage and dosage)2009.10.06HWP9-2. Pyrosin tablets (efficacy, Dosage and Administration) (2009.10.06).hwp
1Pyrocin Tab.Pyrosin tablets (precautions for use)2010.01.19HWP9-1. Pyrosinjeong (Precautions for use) (2010.01.19).hwp